Royal Bank Of Canada reiterated their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a report published on Monday morning, StockTargetPrices.com reports. Royal Bank Of Canada currently has a C$46.00 price target on the specialty pharmaceutical company’s stock.
Other analysts have also issued research reports about the company. TD Securities decreased their price objective on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank decreased their price objective on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of C$38.67.
Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.41 on Monday. The firm’s market capitalization is $11.26 billion. Valeant Pharmaceuticals Intl has a one year low of $24.32 and a one year high of $240.40. The stock’s 50 day moving average price is $36.63 and its 200-day moving average price is $35.33.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.